InMed Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of InMed Pharmaceuticals generated cash of -$6,985,832, which is more than the previous year. Cash used in financing activities reached the amount of $4,654,218 last year. Net change in cash is therefore -$2,340,907.
Cash Flow
| 2015 | -1.60M | -4.84K | 1.74M |
|---|---|---|---|
| 2016 | -386.07K | -885 | 300.13K |
| 2017 | -2.36M | -19.52K | 7.50M |
| 2018 | -3.67M | -1.87M | 19.27M |
| 2019 | -6.67M | -2.10M | 272.5K |
| 2020 | -7.15M | 3.61M | -42.07K |
| 2021 | -9.79M | -1.72K | 10.85M |
| 2022 | -15.58M | -672.99K | 15.07M |
| 2023 | -7.28M | -661.80K | 10.68M |
| 2024 | -6.98M | -9.29K | 4.65M |
INM Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.91M | 6.17M | 7.36M | 5.80M | 9.42M | 18.38M | 5.10M | 41.70K | 128.74K | 6.11K |
Operating activities | ||||||||||
Net income | -7.67M | -7.94M | -18.60M | -10.20M | -8.68M | -10.09M | -6.70M | -3.43M | -1.83M | -3.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 604.51K | 595.99K | 511.78K | 120.86K | 161.96K | 94.71K | -92.77K | 75.21K | 67.40K | 75.75K |
Stock-based compensation expense | 137.71K | 278.15K | 697.89K | 610.19K | 994.40K | 3.11M | 2.43M | 1.16M | 695.20K | 1.68M |
| Deferred income tax benefit | 137.71K | 278.15K | 697.89K | 610.19K | 994.40K | 3.11M | 2.43M | 1.16M | 695.20K | 1.68M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -219.14K | -40.00K | 40.19K | 16.98K | -24.08K | 4.54K | 0 | 0 | 0 |
Inventories | 66.22K | 565.56K | -2.00M | 0 | 0 | 0 | -431.93K | 0 | 0 | 0 |
Accounts payable | 0 | -928.40K | 0 | 0 | 0 | 0 | 431.93K | 0 | 0 | 0 |
Cash generated by operating activities | -6.98M | -7.28M | -15.58M | -9.79M | -7.15M | -6.67M | -3.67M | -2.36M | -386.07K | -1.60M |
Investing activities | ||||||||||
Purchases Of Investments | -42.08K | -42.26K | -425K | 0 | -42.09K | -2.06M | -1.83M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -161.80K | -39.10K | -1.72K | -41.85K | -27.03K | -43.80K | -19.52K | -885 | -4.84K |
Acquisitions Net | 0 | -500K | -208.89K | 0 | 541 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -9.29K | -661.80K | -672.99K | -1.72K | 3.61M | -2.10M | -1.87M | -19.52K | -885 | -4.84K |
Financing activities | ||||||||||
Common Stock Issued | 4.65M | 10.68M | 17.14M | 12.47M | -30.99K | 207.57K | 19.27M | 8.26M | 304.67K | 1.83M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -290.82K | 0 | -71.29K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 4.65M | 10.68M | 15.07M | 10.85M | -42.07K | 272.5K | 19.27M | 7.50M | 300.13K | 1.74M |
Net Change In Cash | -2.34M | 2.73M | -1.18M | 1.55M | -3.63M | -8.57M | 13.25M | 5.11M | -86.81K | 128.07K |
Cash at end of period | 6.57M | 8.91M | 6.17M | 7.36M | 5.79M | 9.80M | 18.35M | 5.15M | 41.92K | 134.18K |
| Data source | Data source | Data source | Data source |